Hepatocyte growth promoting factor combined with antiviral drug in the treatment of chronic hepatitis B and its effect on liver function, viral replication and fibrosis index

Objective: To investigate the clinical efficacy of hepatocyte growth promoting factor (PHGF) combined with antiviral drug in the treatment of Chronic Hepatitis B (CHB) and its effect on viral replication and fibrosis index. Methods: 120 cases of CHB patients in our hospital from January 2014 to August 2016 were randomly divided into treatment group and control group, 60 cases in each group. The control group was treated with entecavir and the treatment group was treated with entecavir plus PHGF. The liver function and liver fibrosis index changes before and after treatment in patients of the two groups were compared, and the negative rate of HBV-DNA was analysed after treatment. Results: Before treatment, the serum levels of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Total Bilirubin (TBIL) of the two groups showed no significant difference (P>0.05). The serum levels of ALT, AST and TBIL of the two groups decreased significantly after treatment, and the treatment group were significantly lower than that of the control group (P 0.05). The serum levels of HA, IV-C, PIIIP and LN of the two groups decreased significantly after treatment, and the treatment group were significantly lower than that of the control group (P 0.05). Conclusion: PHGF combined with antiviral drug treatment of CHB could significantly enhance the antiviral effect and inhibit the progress of liver fibrosis with better clinical efficacy and less adverse reactions for clinical promotion.